Ubiquitin-specific protease 7 accelerates p14ARF degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression

Hepatology

Volumn 61, Issue 5, 2015, Pages 1603-1614

  Cai, Jia Bin ^a   Shi, Guo Ming ^a   Dong, Zhao Ru ^a   Ke, Ai Wu ^a   Ma, Hong Hui ^a   Gao, Qiang ^a   Shen, Zao Zhuo ^a   Huang, Xiao Yong ^a   Chen, Hao ^a   Yu, Ding Dang ^a   Liu, Li Xin ^a   Zhang, Peng Fei ^a   Zhang, Chi ^a   Hu, Mei Yu ^a   Yang, Liu Xiao ^a   Shi, Ying Hong ^a   Wang, Xiao Ying ^a   Ding, Zhen Bin ^a   Qiu, Shuang Jian ^a   Sun, Hui Chuan ^a   Zhou, Jian ^a   Shi, Yujiang G ^a,b   Fan, Jia ^a   more..

^a FUDAN UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEUBIQUITINASE; HORMONE BINDING PROTEIN; MESSENGER RNA; PROTEIN P14; THYROID HORMONE RECEPTOR INTERACTING PROTEIN 12; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN SPECIFIC PROTEASE 7; UNCLASSIFIED DRUG; CARRIER PROTEIN; TRIP12 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; USP7 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DEUBIQUITINATION; DOWN REGULATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEOMICS; TUMOR DIFFERENTIATION; TUMOR INVASION; UBIQUITINATION; UPREGULATION; DISEASE COURSE; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84928211161     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27682     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48:2047-2063.
3. Feinberg A, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
4. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009;78:363-397.
5. Everett RD, Meredith M, Orr A, Cross A, Kathoria M, Parkinson J. A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein. EMBO J 1997;16:1519-1530.
6. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 2005;18:565-576.
7. Wrigley JD, Eckersley K, Hardern IM, Millard L, Walters M, Peters SW, et al. Enzymatic characterisation of USP7 deubiquitinating activity and inhibition. Cell Biochem Biophys 2011;60:99-111.
8. Nathan JA, Sengupta S, Wood SA, Admon A, Markson G, Sanderson C, Lehner PJ. The ubiquitin E3 ligase MARCH7 is differentially regulated by the deubiquitylating enzymes USP7 and USP9X. Traffic 2008;9:1130-1145.
9. Zhang Y, Zhou L, Rouge L, Phillips AH, Lam C, Liu P, et al. Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nat Chem Biol 2013;9:51-58.
10. Giovinazzi S, Morozov VM, Summers MK, Reinhold WC, Ishov AM. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase. Cell Death Differ 2013;20:721-731.
11. Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 2005;4:1166-1170.
12. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 2004;428:1 p following 486.
13. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009;8:2286-2295.
14. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, Colland F, et al. FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nat Cell Biol 2006;8:1064-1073.
15. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, Pandolfi PP. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008;455:813-817.
16. Ma H, Chen H, Guo X, Wang Z, Sowa ME, Zheng L, et al. M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability. Proc Natl Acad Sci U S A 2012;109:4828-4833.
17. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-653.
18. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503.
19. Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008;134:1155-1163.
20. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, et al. CD151 amplifies signaling by integrin alpha6beta1 to PI3K and induces the epithelial-mesenchymal transition in HCC cells. Gastroenterology 2011;140:1629-1641.e15.
21. Huang XY, Ke AW, Shi GM, Zhang X, Zhang C, Shi YH, et al. alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 2013;57:2235-2247.
22. Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding ZB, et al. CD151 modulates expression of matrix metalloproteinase 9 and promotes neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 2010;52:183-196.
23. Hui B, Shi YH, Ding ZB, Zhou J, Gu CY, Peng YF, et al. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer 2012;118:5560-5571.
24. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010;70:10202-10212.
25. Zaman MM, Nomura T, Takagi T, Okamura T, Jin W, Shinagawa T, et al. Ubiquitination-deubiquitination by the TRIM27-USP7 complex regulates tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 2013;33:4971-4984.
26. Maertens GN, El Messaoudi-Aubert S, Elderkin S, Hiom K, Peters G. Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor. EMBO J 2010;29:2553-2565.
27. Noguera NI, Song MS, Divona M, Catalano G, Calvo KL, García F, et al. Nucleophosmin/B26 regulates PTEN through interaction with HAUSP in acute myeloid leukemia. Leukemia 2013;27:1037-1043.
28. Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, et al. NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function. Mol Cell 2012;48:445-458.
29. Chen D, Shan J, Zhu WG, Qin J, Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010;464:624-627.
30. Chio II, Sasaki M, Ghazarian D, Moreno J, Done S, Ueda T, et al. TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nat Cell Biol 2012;14:625-633.
31. Zhang C, Guo X, Zhang L, Lu Z, Ma N, Cheng Y, et al. Methylation-related silencing of p14ARF gene correlates with telomerase activity and mRNA expression of human telomerase reverse transcriptase in hepatocellular carcinoma. J Surg Oncol 2008;98:462-468.
32. Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S, et al. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology 2002;36:427-432.
33. Fukai K, Yokosuka O, Imazeki F, Tada M, Mikata R, Miyazaki M, et al. Methylation status of p14ARF, p15INK4b, and p16INK4a genes in human hepatocellular carcinoma. Liver Int 2005;25:1209-1216.
34. Faesen AC, Luna-Vargas MP, Sixma TK. The role of UBL domains in ubiquitin-specific proteases. Biochem Soc Trans 2012;40:539-545.
35. Felle M, Joppien S, Nemeth A, Diermeier S, Thalhammer V, Dobner T, et al. The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 and regulates the stability of UHRF1. Nucleic Acids Res 2011;39:8355-8365.